Journal of Critical Care
Volume 21, Issue 1 , Pages 38-47 , March 2006

Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001

  • R. Phillip Dellinger, MD

      Affiliations

    • Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08854, USA
    • Section of Critical Care Medicine, Cooper University Hospital, Camden, NJ 08103, USA
    • ,
  • Edward Abraham, MD

      Affiliations

    • Administrative Affairs, Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    • ,
  • Gordon Bernard, MD

      Affiliations

    • Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    • ,
  • John C. Marshall, MD

      Affiliations

    • Department of Surgery and Interdepartmental Division of Critical Care, Toronto General Hospital, University Health Network, 9 EN-234 Toronto, Ontario, Canada M5G 2C4
    • Department of Intensive Care, Erasme University Hospital, 1070 Brussels, Belgium
    • ,
  • Jean-Louis Vincent, MD, PhD

      Affiliations

    • Department of Intensive Care, Erasme University Hospital, 1070 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 555 3380; fax: +32 2 555 4555.

Received 9 July 2004 ,Revised 17 January 2005 ,Accepted 12 July 2005.

References 

  1. Ohlsson K, Björk P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990;348:550–552
  2. Bodmer M, Fournel MA, Hinshaw LB. Preclinical review of anti-tumor necrosis factor monoclonal antibodies. Crit Care Med. 1993;21:S441–S446
  3. Otero-Anton E, Gonzalez-Quintela A, Lopez-Soto A, et al. Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res. 2001;33:77–79
  4. Remick D, Manohar P, Bolgos G, et al. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock. 1995;4:89–95
  5. Marshall JC. The effects of granulocyte colony-stimulating factor in preclinical models of infection and acute inflammation. Shock. 2005;24(Suppl 1):120–129
  6. Arndt P, Abraham E. Immunological therapy of sepsis: experimental therapies. Intensive Care Med. 2001;27(Suppl 1):S104–S115
  7. Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis?. Crit Care Med. 2004;32:S219–S222
  8. The ARDS Network . Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301–1308
  9. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409–417
  10. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F (ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32:2173–2182
  11. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA. 1997;277:1058–1063
  12. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638–1652
  13. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–710
  14. Bernard GR, Doig BG, Hudson G, Lemeshow S, Marshall S, Russell JC, et al. Quantification of organ failure for clinical trials and clinical practice. [abstract] Am J Respir Crit Care Med. 1995;151:A323
  15. Kress JP, Christenson J, Pohlman AS, et al. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med. 1999;160:1957–1961
  16. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentric, prospective study. Crit Care Med. 1998;26:1793–1800
  17. Lopes Ferreira F, Peres Bota D, Bross A, et al. Serial evaluation of the SOFA score to predict outcome. JAMA. 2001;286:1754–1758
  18. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  19. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31:834–840

PII: S0883-9441(05)00205-4

doi: 10.1016/j.jcrc.2005.07.002

Journal of Critical Care
Volume 21, Issue 1 , Pages 38-47 , March 2006

Article Tools